Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-25 17:12 CEST (UTC+2h)

Nonbinding futility rule [Two-Stage / GS Designs]

posted by d_labes - Berlin, Germany, 2018-06-14 10:47  - Posting: # 18906
Views: 504

(edited by d_labes on 2018-06-14 10:58)

Dear Ben,

» The reference at page 19 actually refers to the CI futility criterion,

I know.

» ... in my opinion the only possibility is: if you want to be able to handle it in a nonbinding manner, then you have to go with conditional error rates only (i.e. you cannot use the estimated conditional target power as target power for calculation of n2). So, we would need to select ssr.conditional = "error".

My first thought was: Set fCpower = 1, that results in do not use the power futility criterion. This gives n2=16 for mittyri's example, CV1=0.2575165, n1=38, fCpower=1).

Your suggestion, CV1=0.2575165, n1=38, ssr.conditional = "error")
gives also n2=16. Astonishing or correct?

Avoiding the conditional sample size re-estimation, i.e. using the conventional sample size re-estimation via, CV1=0.2575165, n1=38, ssr.conditional = "no")
gives n2=4. Ooops? Wow!

Helmuts caveat of how to decide in case of "nonbinding futility" needs to be considered, scientifically, not via NLYW :-D.
IIRC the term "nonbinding" in the context of sequential designs is used for flexibility in stopping or continuing due to external reasons. Do we have such here?

Binding, nonbinding - does it have an impact on the alpha control? I think not, but are not totally sure.



Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,428 posts in 3,913 threads, 1,176 registered users;
online 31 (0 registered, 31 guests [including 20 identified bots]).

Lack of clarity is always a sign of dishonesty.    Celia Green

BEBAC Ing. Helmut Schütz